Akorn, Inc.

1925 West Field Court, Suite 300,
Lake Forest, Illinois 60045
United States,
(847) 279-6100
www.akorn.com

Akorn, Inc. is a niche generic pharmaceutical company engaged in the development, manufacture and marketing of multi-source and branded pharmaceutical products in the areas of ophthalmology, antidotes, anti-infectives, and controlled substances for pain management and anesthesia in the United States and across the globe. Akorn, Inc. was founded in 1971 and is based in Lake Forest, Illinois.

M&A Summary

Buy vs Sell

Year ≤ '12 '13 '14 '15 '16 '17 T
Buy (0.6/yr) # 2 1 2 - - - 5
vol $26M $640M $485M $1.2B
Sell (0.4/yr) # - - 2 - - - 2
vol $120M $120M
  7

Top M&A Advisors

Financial Deals
Sign-up to View
2
Legal Deals
Sign-up to View
2
Sign-up to View
1

Deal Values

Buy # TOTAL
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
TOTAL Sign-up to View
Largest Hi-Tech Pharmacal Co., Inc.
$640M (2013-08-27)
Sell # Total
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
Total Sign-up to View
Largest Aciex Therapeutics, Inc.
$120M (2014-10-24)

Akorn was acquired by Fresenius Kabi USA on April 24, 2017.

Akorn has acquired 5 companies of its own, including 3 in the last 5 years. A total of 1 acquisition came from private equity firms. It has also divested 2 assets.

Akorn’s largest acquisition to date was in 2013, when it acquired Hi-Tech Pharmacal for $640M. It’s largest disclosed sale occurred in 2014, when it sold Aciex Therapeutics to Nicox SA for $120M. Akorn has acquired in 4 different US states. The Company’s most targeted sectors include life science (40%) and medical products (40%).

When analyzing the life science sector as a whole, according to Mergr, in the last 3 years, there are 410 life science companies that have made at least 1 acquisition, 23 have acquired at least 5 companies, and 3 have acquired more than 10 companies. The most prolific strategic life science acquirer over the past 3 years is Eurofins Scientific SA, with 25 acquisitions. The most prolific private equity acquirer in the life science sector over the past 3 years is Ampersand Capital Partners with 4 platform acquisitions.

Join Mergr and gain access to Akorn’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.


What's Mergr?

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 3.3K Private Equity Firms
  • 113K M&A Transactions
  • 123K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 2.7K M&A Advisors
    (Investment Banks and Law Firms)
  • 37K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.